INTRODUCTION
As a consequence of their terminally differentiated phenotype, cardiac myocytes respond to growth stimuli by increasing in size rather than by undergoing cell division. This hypertrophic response also involves characteristic changes in gene expression, including the rapid induction of immediate-early genes such as cfos, the up-regulation of certain contractile protein genes such as ventricular myosin light chain-2 (vMLC2) and the re-expression of fetal genes such as atrial natriuretic factor (ANF) and skeletal muscle α-actin (SkαA) [1] . The most potent hypertrophic agonists include endothelin-1 (ET-1) and the α " -adrenoceptor agonist phenylephrine (PE). These agonists interact with G q -coupled receptors to initiate signalling cascades involving small G proteins, such as Ras and Rho, as upstream components. Even at this early stage it is clear that multiple pathways are involved in the transmission of the hypertrophic signal, since Ras and Rho appear to be on distinct branches [2] . Further downstream there is abundant evidence that one or more of the family of mitogenactivated protein kinases (MAPKs) is involved in transmitting the signal to the nucleus (reviewed in [3] ).
MAPKs are classified into the extracellular signal-regulated kinases (ERKs) and the stress-activated MAPKs, which themselves are subdivided into the c-Jun N-terminal kinases (JNKs) and the p38MAPKs. ERKs are activated by classical hypertrophic agonists, such as PE, ET-1 and the protein kinase C activator PMA, whereas the stress-activated MAPKs are activated more strongly by cell stresses, such as ischaemia\ Abbreviations used : ANF, atrial natriuretic factor ; AP-1, activator protein 1 ; β-gal, β-galactosidase ; β-MHC, β-myosin heavy chain ; ET-1, endothelin-1 ; FLAG, DYKDDDDK ; JNK, c-Jun N-terminal kinase ; JIP-1, JNK-interacting protein 1 ; LUX, luciferase ; ERK, extracellular signal-regulated kinase ; MAPK, mitogen-activated protein kinase ; MKK, MAPK kinase ; MEK, MAPK/ERK kinase ; MEKK, MEK kinase ; PE, phenylephrine ; RSV, Rous sarcoma virus ; SkαA, skeletal muscle α-actin ; SRE, serum-responsive element ; vMLC2, ventricular myosin light chain-2. 1 To whom correspondence should be addressed (e-mail stephen.fuller!ic.ac.uk).
PMA, which does not activate JNK significantly in myocytes, was much less affected by overexpression of JIP-1. JIP-1 also failed to inhibit reporter gene activation in response to constitutively active Ras or Raf, but attenuated reporter gene activation induced by a constitutively active mutant of mitogenactivated protein kinase kinase kinase 1 (MEKK1), an upstream kinase that preferentially activates JNKs, by 50 %. Overexpression of JIP-1 also significantly reduced the increase in cell area in response to PE from 63 % to 56 %, but had no effect on the increase in cell size in response to ET-1 (38 %). These results suggest that activation of the JNK pathway contributes to the transcriptional and morphological responses to G q receptorcoupled hypertrophic agonists.
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reperfusion, osmotic shock and inhibitors of protein synthesis. Much recent evidence points to a role for stress-activated MAPK activation in cardiac hypertrophy. First, overexpression of MAPK\ERK kinase kinase 1 (MEKK1) or MAPK kinase 7 (MKK7), upstream activators of the JNK pathway, induces transcriptional and morphological features of the hypertrophic response [4, 5] . Secondly, the JNK pathway is activated in the hypertrophied hearts of transgenic mice overexpressing oncogenic Ras [6] . Thirdly, adenoviral-mediated transfer of a dominant negative mutant of SEK-1, the immediate upstream activator of the stress-activated protein kinases (JNKs), inhibited ET-1-induced hypertrophic responses in itro [7] and left ventricular hypertrophy in i o [8] . Finally, transfection of myocytes with MKK6(Glu), which specifically activates p38MAPK, induces a hypertrophic response, and SB 203580, a specific inhibitor of p38MAPK, inhibits the hypertrophic response to MKK6(Glu) and to PE [9] . Determination of the extent to which individual MAPK pathways contribute to the response of hypertrophic agonists is dependent upon the ability to inhibit their activation selectively. Pharmacological inhibitors have been developed which are able to inhibit ERK activation (the MEK1 inhibitors PD98059 and U0126) and p38MAPK activity (SB203580) with a reasonable degree of specificity, but no commercial inhibitor is available which is specific for the JNK pathway. To circumvent this deficiency we have used JNK-interacting protein 1 (JIP-1). Although JIP-1 is now understood to be a cytosolic scaffold protein whose function is to selectively mediate JNK activation [10] , JIP-1 was originally identified as a cytosolic anchor protein that binds specifically to JNK [11] . Overexpression of JIP-1 causes retention of JNK in the cytoplasm and prevents its signalling activity [11] . We have used this property of JIP-1 to determine the consequences of inhibiting JNK signalling on the response to hypertrophic agonists in cardiac myocytes. The findings support the view that signalling through JNK is an important component of the transcriptional response to ET-1 and PE, but that the increase in cell size caused by these agonists is largely independent of nuclear JNK activity.
EXPERIMENTAL

General materials
Sprague-Dawley rats were bred within the National Heart and Lung Institute, Imperial College, London, U.K. ET-1 was from Bachem, Saffron Walden, Essex, U.K. Culture medium and other reagents were from Sigma, Life Technologies, Marathon Laboratory Supplies (London, U.K.) or Merck, as described previously [12] . PE was prepared freshly on the day of use.
Expression and reporter constructs
DYKDDDDK (FLAG)-tagged JNK-binding domain of JIP-1 [11] from mouse brain was expressed from the vector pcDNA3 (Invitrogen). The rat ANF-luciferase (ANF-LUX) reporter construct pANF(k3003)L∆5h (ANF3003LUX) [13] , the vMLC2-LUX construct pMLC(k2700 to j18)L∆5h (vMLC2700LUX) [14] , the Rous sarcoma virus (RSV)-LUX construct and pON249 [15] , in which β-galactosidase ( β-gal) is expressed from a constitutive cytomegalovirus (CMV) promoter, were kindly provided by Professor K. R. Chien (Department of Medicine, University of California San Diego, CA, U.S.A.). The activator protein 1 (AP-1)-LUX construct TRE2PRL(k36) was a gift from Dr J. H. Brown (Department of Pharmacology, University of California San Diego) and Dr M. G. Rosenfeld (Howard Hughes Medical Institute, University of California San Diego). The LUX reporter constructs for rat β-myosin heavy chain ( β-MHC) [16] , the mouse c-fos serum-responsive element (SRE) [17] and the chicken SkαA promoter [18] were gifts from Dr M. D. Schneider (Molecular Cardiology Unit, Baylor College of Medicine, Houston, TX, U.S.A.), and have been described in detail previously [19] . Plasmids were purified by poly(ethylene glycol) precipitation [20] .
Transient transfection of cultured neonatal rat ventricular myocytes
Ventricular myocytes were isolated from the hearts of 1-2-dayold rats by a modification of the method of Iwaki et al. [21] , as described previously [19] . After a 30 min pre-plating to decrease fibroblast contamination, myocytes for transfection were plated on gelatin-coated 60 mm tissue culture dishes at a density of 1 million cells per dish (350 cells\mm#). Cells were maintained at 37 mC in a humidified atmosphere of 5 % CO # . At 24 h after plating and 4 h before transfection, medium was changed to 4 % horse serum in maintenance medium [Dulbecco's modified and an equal volume of 50 mM Bes (pH 7.1), 280 mM NaCl, 1.5 mM Na # HPO % was added. After 20 min, 0.5 ml of this suspension was added to 4 ml of medium on each plate. After overnight transfection, cells were washed once with 10 % horse serum in maintenance medium and twice with maintenance medium before addition of agonists where indicated. After 48 h, myocytes were washed three times with ice-cold PBS and extracted on ice with 0.1 M potassium phosphate (pH 7.9), 0.5 % (v\v) Triton X-100 and 1 mM dithiothreitol (0.4 ml) for 15 min. Assays for LUX and β-gal were performed as detailed previously [19] . Results are presented as the meanspS.E.M. of experiments on five separate preparations of myocytes and using at least two separate preparations of plasmids. The transfection efficiency is routinely 1-2 % [19], but was not specifically assessed in these experiments.
Immunoprecipitation experiments
Myocytes were plated at a density of 4 million cells per 60 mm culture dish and were transfected with 10 µg of either Myctagged ERK2 or FLAG-tagged p38MAPK, together with 10 µg of JIP-1 or pcDNA3 backbone vector. After overnight incubation, cells were washed as above and incubated for a further 24 h in the absence of agonist. Myocytes were then exposed to 100 µM PE for 5 min (ERK2 activation) or 0.5 M sorbitol for 30 min (p38MAPK activation). The cells were then washed twice with PBS and extracted in 200 µl of extraction medium [10 mM Tris\HCl, pH 7.4, 5 mM EDTA, 50 mM NaF, 50 mM NaCl, 2 mM Na 
Assay of activated ERK and p38MAPK in immunoprecipitates
Determination of active ERK and p38MAPK was carried out by Western blotting on 10 % SDS gels. After transfer to PVDF membranes using a Bio-Rad semi-dry blotter, membranes were blocked for 30 min with 5 % non-fat milk powder, briefly rinsed in TBST buffer [10 mM Tris\HCl (pH 8.0), 150 mM NaCl, 0.05 % (v\v) Tween 20] and incubated overnight at 4 mC with primary antibodies in 5 % (w\v) BSA in TBST. The antibodies were phospho-specific ERK and p38MAPK antibodies (New England Biolabs) and were used at a concentration of 1 in 1000. After washing in TBST (3i5 min), incubating with a horseradish peroxidase-linked secondary antibody and re-washing, blots were probed with an ECL2 kit (Amersham International) and exposed to Hyperfilm (Amersham International). Immunoblots were quantified by laser densitometry.
Localization of JIP-1 in myocytes
To assess JIP-1 localization in myocytes, cells were transfected with JIP-1 or backbone vector and incubated for 24 h in the absence of serum before extraction and separation into cytosolic and nuclear fractions, as follows : after washing in PBS, cells were scraped into 150 µl of buffer A [10 mM Hepes (pH 7.9), 10 mM KCl, 1.5 mM MgCl # , 0.3 mM Na $ VO % , 200 µM leupeptin, 10 µM E-64, 5 mM dithiothreitol and 300 µM PMSF]. Extracts were centrifuged (10 000 g for 5 min at 4 mC) and the supernatant (cytosolic) fraction boiled after addition of 50 µl of c-Jun N-terminal kinase-interacting protein 1 and gene expression in cardiac myocytes SDS\PAGE sample buffer. The pellets were resuspended in 150 µl of buffer A containing 0.1 % (v\v) Nonidet P40, mixed and incubated on ice for 10 min. After centrifugation (10 000 g, 5 min, 4 mC), the supernatants were discarded and the pellets resuspended in buffer B [20 mM Hepes (pH 7.9), 420 mM NaCl, 1.5 mM MgCl # , 0.2 mM EDTA, 25 % (v\v) glycerol, 0.3 mM Na $ VO % , 200 µM leupeptin, 10 µM E-64, 5 mM dithiothreitol and 300 µM PMSF]. The samples were extracted on ice for 1 h, centrifuged (10 000 g for 5 min at 4 mC) and the supernatant nuclear extracts boiled with 20 µl of SDS\PAGE sample buffer. Extracts were then subjected to Western blotting using antibodies against the FLAG-tagged epitope of the JIP-1 construct [M2 antibody (Sigma) used at 1 : 4000] and histone H3 [rabbit polyclonal (New England Biolabs) used at 1 : 1000].
Determination of myocyte size
To assess the area of transfected myocytes, cells were washed three times with ice-cold PBS, fixed with 4 % formaldehyde in PBS for 10 min, re-washed three times with PBS and then stained with 0.2 mg\ml 5-bromo-4-chloroindol-3-yl β--galactopyranos-
Transfected (blue) cells were randomly selected and imaged using a video hardcopier from which the cell area was determined by planimetry.
Expression of results and statistical analysis
All transfection data are expressed as the ratio of reporter gene expression in the presence of JIP-1 relative to empty vector controls and are corrected for β-gal expression from the cotransfected pON249 plasmid. Results are presented as means pS.E.M. for the number of separate myocyte preparations shown in the Figure legends. Statistical significance was assessed by using a paired or unpaired Student's t test, as appropriate, with a significant difference taken at P 0.05.
RESULTS
JIP-1 inhibits the stimulation of gene expression induced by ET-1 and PE
To investigate the effects of JIP-1 on the stimulation of gene expression, myocytes were co-transfected with JIP-1 and LUX reporter constructs under the control of gene promoters known to be responsive to hypertrophic agonists. Treatment of myocytes with 0.1 µM ET-1, 100 µM PE or 1 µM PMA induced expression of a transfected ANF3003LUX transgene by 4.7p1.5-fold (P 0.05), 30.6p6.2-fold (P 0.01) and 2.8p1.7-fold respectively ( Figure 1A) . Expression of JIP-1 inhibited ANF3003LUX expression in response to ET-1, PE and PMA by 45 %, 56% and 73 % respectively. Basal ANF3003LUX expression was also inhibited by JIP-1. Using a β-MHC-LUX reporter, ET-1, PE and PMA induced expression by 5.2p3.1-fold, 20.3p4.6-fold (P 0.02) and 5.2p0.7-fold (P 0.01) respectively ( Figure 1B) . JIP-1 inhibited PE-induced β-MHC-LUX expression by 48 % and ET-1-induced β-MHC-LUX expression by 56 %, but had little effect on PMA-induced β-MHC-LUX activity. Similarly, JIP-1 inhibited PE-and ET-1-induced vMLC2700LUX expression by more than 60 %, but had a much smaller effect on vMLC2700LUX expression induced by PMA (Figure 2A) . Part of the reason for the lesser effect of JIP-1 on PMA-induced gene expression might be related to the observation that the ANF, β-MHC and vMLC transgenes are less responsive to PMA than to either ET-1 or PE. To assess this possibility, the effect of JIP-1 was tested on other transgenes that respond to PMA equally well or better than to PE and ET-1. A SkαA reporter gene was stimulated by 3.1p0.8-fold, 3.2p0.6-fold and 5.1p0.9-fold by ET-1, PE-and PMA respectively ( Figure 2B ). Expression of JIP-1 inhibited the response to ET-1 (by 86 %) and PE (by 60 %), but had a lesser effect on PMA-induced SkαA expression (22 %), despite the fact that the response to PMA was greater. This suggests that the relative lack of effect of JIP-1 on PMA-induced activation of the β-MHC and vMLC2 transgenes was not simply a manifestation of the lower response of these genes to PMA. This conclusion was reinforced in experiments using an AP-1-LUX reporter gene ( Figure 3A ). This construct contains two consensus AP-1 binding sites (also known as PMA responsive elements) linked to a minimal prolactin promoter and is much more responsive to PMA than to ET-1 or PE in cardiac myocytes. PMA induced a 25-fold activation of this reporter gene, but the inclusion of JIP-1 led to only a modest and non-significant reduction in expression. In contrast, the stimulation of expression of a c-fos-SRE transgene, in which the upstream SRE of the murine c-fos promoter is juxtaposed to a minimal c-fos promoter [17] , was inhibited by JIP-1 to a similar extent in the presence of all three agonists ( Figure 3B ). The sensitivity of different reporter genes to inhibition by JIP-1 presumably reflects the extent to which they are dependent on activation of JNK for their expression. To confirm that the effects of JIP-1 on reporter gene expression were specific for genes responsive to hypertrophic stimuli, its effect on an RSV-LUX reporter was determined. The RSV promoter is constitutively active and LUX expression from this transgene is one to two orders of magnitude greater than that from the inducible LUX transgenes used in this study. As expected, JIP-1 was unable to reduce expression of RSV-LUX (expression in the presence of JIP-1 was 100.3p12.9 % of the control, n l 5).
JIP-1 inhibits JNK-mediated gene expression but not ERKmediated gene expression
Hypertrophic agonists, such as PE and ET-1, are able to activate multiple signalling pathways in cardiac myocytes, including the ERK, JNK and p38MAPK pathways. Since all three pathways have been implicated in the transcriptional response to hypertrophic agonists [5] [6] [7] [22] [23] [24] [25] , it is not surprising that JIP-1 is only able to partially inhibit the response. To gain further insight into the selectivity of the inhibitory effects of JIP-1 on myocyte gene expression, myocytes were transfected with intracellular signalling components upstream of the ERK and JNK pathways. Transfection of myocytes with constitutively active Ras ( Figure  4A ) or Raf ( Figure 4B ), upstream activators of the ERK pathway, stimulated ANF3003LUX expression 2-3-fold, as we have reported previously [26] . In keeping with its specific role in JNK activation, JIP-1 failed to inhibit ANF-LUX expression in response to Ras or Raf. In contrast, JIP-1 inhibited the stimulation of ANF-LUX expression elicited by constitutively active MEKK1, an upstream activator of the JNK cascade, by approx. 50 % (Figure 4C) . Although it is possible that JIP-1 could exert its effect on MEKK1-stimulated ANF3003LUX expression by reducing MEKK1 transcription, this is unlikely because Ras, Raf and MEKK1 were all expressed from strong viral promoters and JIP-1 only affected the response to MEKK1. Thus overexpression of JIP-1 inhibits transcriptional responses mediated through JNK, but not those mediated through ERK activation in cardiac myocytes.
Effect of overexpression of JIP-1 on cell size
ET-1 and PE increased myocyte area by 38 % and 63 % respectively in this series of experiments ( Table 1) . Expression of JIP-1 had no effect on the increase in cell size elicited by ET-1, but reduced myocyte area in response to PE by 14 %, and this was statistically significant. However, this effect was similar in magnitude to the effect of JIP-1 on cell size in the absence of agonist (10 %), and was modest in comparison with the effect of JIP-1 on PE-induced transcription.
JIP-1 does not prevent activation of ERK or p38MAPK in cardiac myocytes
To determine whether JIP-1 selectively acts on the JNK pathway in cardiac myocytes, as has been demonstrated in Chinesehamster ovary cells [11] , its effects on ERK and p38MAPK activation were determined. Treatment of myocytes with PE for 5 min induced activation of a transfected Myc-tagged ERK2 construct, as determined using a phospho-ERK antibody following immunoprecipitation ( Figure 5A ). Co-transfection with JIP-1 had no effect on the ability of PE to induce ERK activation c-Jun N-terminal kinase-interacting protein 1 and gene expression in cardiac myocytes 
Table 1 Effect of JIP-1 on myocyte size
Neonatal myocytes (5i10 5 cells per 60 mm dish) were transfected with 4 µg of pON249 and 10 µg of JIP-1 or pcDNA3 backbone vector per dish, as described in the Experimental section. After a further 48 h the cells were fixed and stained with X-Gal and cell area was measured by planimetry. Results are meanspS.E.M. of 100 randomly chosen transfected cells. Statistical significance was assessed by an unpaired t test. *P 0.001 for the effect of agonist ; †P 0.01 for the effect of JIP-1 versus pcDNA3.
(compare lanes 2 and 3). Lane 4 shows a positive control in which endogenous ERK2 ( p42) and ERK1 (p44) activation was measured following PE stimulation. The Myc tag on the transfected ERK2 construct (lanes 1-3) reduces its mobility on the gel
Figure 5 Effect of JIP-1 on ERK and p38MAPK activity in cardiac myocytes
Neonatal myocytes (4 million cells per 60 mm dish) were transfected overnight with 10 µg of either Myc-tagged ERK2 (A) or FLAG-tagged p38MAPK (B), together with 10 µg of JIP-1 or pcDNA3 backbone vector (Con) and incubated for a further 24 h in the absence of agonist. Myocytes were then exposed to 100 µM PE for 5 min (A) or 0.5 M sorbitol for 30 min (B) before extraction and assay for active ERK and p38MAPK, as described in the Experimental section. Lane 4 of (A) and lane 5 of (B) are extracts from non-transfected myocytes in the presence of agonist to illustrate the activation and relative mobility of the endogenous ERKs and p38MAPK. Experiments were repeated with similar results.
Figure 6 JIP-1 is localized in the cytoplasm in cardiac myocytes
Neonatal myocytes (4 million cells per 60 mm dish) were transfected overnight with 10 µg of JIP-1 or pcDNA3 backbone vector (Con) and incubated for a further 24 h in the absence of agonist. Myocytes were then extracted and separated into cytosolic (C) and nuclear (N) fractions and blotted for JIP-1 (anti-FLAG) and histone H3 as described in the Experimental section.
causing it to migrate between the bands for endogenous ERK1 and ERK2 (lane 4). In an analogous experiment for p38MAPK ( Figure 5B ), JIP-1 also failed to have any effect on the activation of p38MAPK in response to 0.5 M sorbitol, a strong activator of the p38MAPK pathway in cardiac myocytes. Here, again, the epitope tag slightly reduces the mobility of the p38MAPK relative to the endogenous p38MAPK control ( Figure 5B , lane 5). Finally, we determined that the JNK-binding domain of JIP-1 when overexpressed is localized almost exclusively to the cytoplasmic fraction in cardiac myocytes ( Figure 6 ). As a control, cytosolic and nuclear fractions were blotted for histone H3, which, as expected, was found in the nuclear fraction with only a minor contamination of the cytoplasmic fraction. It is possible, therefore, that overexpression of JIP-1 inhibits the transcriptional responses to hypertrophic agonists in cardiac myocytes by sequestering JNK in the cytoplasm, as found in other cells.
DISCUSSION
The G q -coupled receptor agonists ET-1 and PE induce a potent hypertrophic response in cardiac myocytes. This hypertrophic response is Ras-dependent [27] , but determination of the downstream signalling pathways through which activated Ras mediates the response is complicated by the fact that activated Ras interacts with multiple effectors. These include Raf, RalGDS, MEKK1, phosphoinositide 3-kinase and protein kinase Cζ [28] . Of these, Raf [6, 26, 29] and MEKK1 [4, 6] have been shown to induce ANF expression when constitutively active mutants are expressed in cardiac myocytes, and are the most likely mediators of the hypertrophic response. Signalling from Raf proceeds through MEK1\2 to the ERKs and several lines of evidence [19, 22, 23] , but not all [30, 31] , have implicated this pathway in hypertrophy. For MEKK1, the distal signalling pathway involves activation of JNKs through the intermediary kinase MKK4\7, and introduction of activated MKK7 into myocytes by means of an adenoviral vector produces a hypertrophic phenotype in these cells [5] . Thus both the ERK and JNK pathways are activated in myocytes in response to G q receptor-coupled hypertrophic agonists, and activation of both pathways may be necessary for the full hypertrophic response.
In comparison with ET-1 and PE, PMA is a very poor activator of JNKs in cardiac myocytes, which presumably explains why JIP-1 generally had a lesser effect on PMA-induced gene expression than on gene expression induced by ET-1 or PE. The lack of dependence of PMA-induced gene expression on JNK activity is, perhaps, somewhat surprising given that a major target for the transcriptional effects of PMA is through activation of AP-1, a protein complex comprised of Jun-Jun or Fos-Jun dimers. The ability of PMA to induce transcriptional effects through the AP-1 complex in myocytes was ably illustrated using an AP-1-dependent reporter gene ( Figure 3A) , for which two consensus AP-1 sites are the only cis-elements. Significantly, this reporter gene is much more strongly activated by PMA than by either ET-1 or PE. Since the activation of this construct by PMA was only partially and non-significantly inhibited by JIP-1, this suggests that there is likely to be sufficient nuclear JNK activity to produce functional (phosphorylated) Jun-Jun or Fos-Jun dimers. Moreover, the poor activation of JNKs that PMA induces in myocytes may be offset by the increase in c-Fos and c-Jun expression that PMA elicits to produce an effective AP-1 transcription factor complex.
One reporter gene whose induction by PMA was substantially inhibited by JIP-1 was the c-fos-SRE reporter gene, in which the SRE of the c-fos gene has been juxtaposed to a minimal c-fos promoter. The SRE binds a complex that includes the serum response factor and ternary complex factors, of which most attention has been focused on Elk-1. Although the serum response factor is rapidly phosphorylated in response to growth factors, phosphorylation of Elk-1 provides the major regulatory input to activation at the SRE [32] . Elk-1 is one of the major targets for phosphorylation by the ERKs, which explains the potent activation of the c-fos-SRE reporter gene by PMA and by ET-1 and PE. However, Elk-1 can also be phosphorylated by JNKs [33] , which may explain the sensitivity of c-fos-SRE induction by ET-1 and PE to JIP-1, but which is less likely to explain inhibition of PMA-induced c-fos-SRE expression, since PMA activates JNKs poorly. Nevertheless, it is noteworthy that JIP-1 inhibits basal c-fos-SRE expression, and there may therefore be a low level of nuclear JNK activity that is required irrespective of agonist.
A consistent observation is that inhibition of ET-1-or PEinduced gene expression by JIP-1 is incomplete and rarely much more than 50 %. This might reflect an incomplete blockade of the JNK pathway by overexpression of JIP-1 and\or that ET-1 and PE utilize pathways in addition to JNK for activating transcription. Since ET-1 and PE both activate Ras in cardiac myocytes [34] , and the stimulation of gene expression by Ras is not prevented by overexpression of JIP-1 (Figure 4) , signalling through the Ras-Raf-MEK-ERK pathway may account for the JIP-1-insensitive effects of ET-1 and PE on transcription. A similar explanation may also account for the partial inhibition of the transcriptional response to MEKK1 by JIP-1. MEKK1 is an upstream component of the JNK pathway and was originally isolated as a protein able to interact with MEK1 [35] . According to one report [36] , MEKK1 phosphorylates MEK1 on serine-118 and serine-222, the same sites as are phosphorylated by Raf, but does not activate ERKs. However, overexpression of MEKK1 does induce ERK activation in HeLa cells [37] and, since constitutively active MEKK1 was overexpressed in the current experiments, it is likely that ERK was activated too. Thus both the ERK and JNK pathways are likely to contribute to the transcriptional response to ET-1, PE and to overexpression of MEKK1.
Although expression of JIP-1 diminished the increase in myocyte area in response to PE significantly, the magnitude of this effect was much less than its effect on transcription. Moreover, JIP-1 had no effect on basal cell size, nor on its increase in response to ET-1. These results suggest that the increase in cell size in response to hypertrophic agonists is much less dependent on activation of JNK. Alternative possibilities are that JNK activation is required for the increase in cell size, but that its effects are mediated in the cytoplasm rather than in the nucleus, or that sufficient active JNK may reach the nucleus for it to have an effect. Direct activation of the JNK pathway by adenoviral infection with an activated MKK7 construct stimulated an increase in myocyte size [5] , adding weight to this possibility.
In summary, we have shown that overexpression of JIP-1 attenuates the transcriptional responses to hypertrophic agonists in cardiac myocytes. In the absence of specific pharmacological inhibitors of the JNK pathway, overexpression of JIP-1 represents a useful tool with which to assess the consequences of inhibition of JNK activity. Our results suggest that activation of the JNK pathway is part of the mechanism through which hypertrophic agonists exert their transcriptional effects in cardiac myocytes.
